{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:40Z","timestamp":1787020900363,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-024-06910-9","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T10:02:43Z","timestamp":1725357763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Late presentation of chronic myeloid leukaemia patients in a low-income country: the prognostic implications and impact on treatment outcome"],"prefix":"10.1186","volume":"17","author":[{"given":"Elisha A.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim O.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahman A.","family":"Bolarinwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatunde A.","family":"Adeagbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebanjo J.","family":"Adegbola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lateef","family":"Salawu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluseye O.","family":"Bolaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muheez A.","family":"Durosinmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"issue":"1 Suppl 1","key":"6910_CR1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1053\/j.seminhematol.2006.12.007","volume":"44","author":"RH Alvarez","year":"2007","unstructured":"Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007;44(1 Suppl 1):S4\u201314.","journal-title":"Semin Hematol"},{"issue":"6","key":"6910_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709.","journal-title":"Am J Hematol"},{"issue":"2 Pt 1","key":"6910_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1590\/s1679-45082011rb2022","volume":"9","author":"PW Bollmann","year":"2011","unstructured":"Bollmann PW, del Giglio A. Chronic myeloid leukemia: past, present, future. Einstein. 2011;9(2 Pt 1):236\u201343.","journal-title":"Einstein"},{"key":"6910_CR4","first-page":"103","volume":"55","author":"M Usman","year":"2007","unstructured":"Usman M, Syed NN, Kakepoto GN, Adil SN, Khurshid M. Chronic phase chronic myeloid leukemia: response of Imatinib Mesylate and significance of Sokal score, Age and Disease Duration in Predicting the Hematological and Cytogenetic Response. J Assoc Physicians India. 2007;55:103\u20137.","journal-title":"J Assoc Physicians India"},{"key":"6910_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1756-8722-2-30","volume":"2","author":"JP Lee","year":"2009","unstructured":"Lee JP, Birnstein E, Masiello D, Yang D, Yang AS. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. J Hematol Oncol. 2009;2:30. https:\/\/doi.org\/10.1186\/1756-8722-2-30.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"6910_CR6","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-08-1195","volume":"15","author":"F Palandri","year":"2009","unstructured":"Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, et al. Treatment of Philadelphia-Positive chronic myeloid leukemia with Imatinib: importance of a stable molecular response. Clin Cancer Res. 2009;15(3):1059\u201363.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"6910_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","volume":"127","author":"J Preetesh","year":"2016","unstructured":"Preetesh J, Kantarjian H, Keyur PP, Gonzalez GN, Rajyalakshmi L, Rashmi KS. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016;127(10):1269\u201375.","journal-title":"Blood"},{"key":"6910_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajh.24249","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E. Chronic myeloid leukemia: first-line drug of choice. Am J Hematol. 2016;91:59\u201366.","journal-title":"Am J Hematol"},{"issue":"Suppl 2","key":"6910_CR9","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","volume":"94","author":"M Baccarani","year":"2015","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94(Suppl 2):S141\u20137.","journal-title":"Ann Hematol"},{"issue":"4","key":"6910_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Bacarrani M, Tura S, Gomez GA, Robertson JE. Prognostic indication in \u2018good-risk\u2019 chronic granulocytic leukaemia. Blood. 1984;63(4):789\u201399.","journal-title":"Blood"},{"issue":"3","key":"6910_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686\u201392.","journal-title":"Blood"},{"key":"6910_CR12","volume-title":"Chronic myeloid leukemia, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. Chronic myeloid leukemia","author":"NCC Network","year":"2022","unstructured":"Network NCC. Chronic myeloid leukemia, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. Chronic myeloid leukemia. Online: NCCN; 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1427. Downloaded on 30\/07\/2024."},{"issue":"4","key":"6910_CR13","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. EuropeanLeukemiaNet.2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"11","key":"6910_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4314\/eamj.v79i11.8805","volume":"79","author":"NA Othieno-Abinya","year":"2002","unstructured":"Othieno-Abinya NA, Nyabola LO, Kiarie GW, Ndege R, Main JMD. Chronic myeloid leukaemia at Kenyatta National Hospital, Nairobi. East Afr Med J. 2002;79(11):593\u20137.","journal-title":"East Afr Med J"},{"key":"6910_CR15","doi-asserted-by":"publisher","unstructured":"Koffi KG, Nanho DC, N\u2019dathz E, Kouehion P, Dissieka R, Attia A. et.al. The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Cote d\u2019Ivoire. Adv Hematol, Volume 2010, Article ID 268921, https:\/\/doi.org\/10.1155\/2010\/268921","DOI":"10.1155\/2010\/268921"},{"key":"6910_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-016-2238-9","volume":"16","author":"T Beinortas","year":"2016","unstructured":"Beinortas T, Tavorien\u0117 I, \u017dvirblis T, Gerbutavi\u010dius R, Jurgutis M, Gri\u0161kevi\u010dius L. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000\u20132013. BMC Cancer. 2016;16:198\u2013207.","journal-title":"BMC Cancer"},{"issue":"6","key":"6910_CR17","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29(6):1336\u201343.","journal-title":"Leukemia"},{"key":"6910_CR18","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1186\/s13104-018-3890-8","volume":"11","author":"LT Nguyen","year":"2018","unstructured":"Nguyen LT, Guo M, Naugler C, Rashid-Kolvear F. Incidence of chronic myeloid leukemia in Calgary, Alberta, Canada. BMC Res Notes. 2018;11:780\u20134.","journal-title":"BMC Res Notes"},{"key":"6910_CR19","doi-asserted-by":"crossref","unstructured":"Thompson PA, Kantarjian H, Cortes JE. Diagnosis and Treatment of Chronic Myeloid Leukemia (CML) in 2015. Mayo Clin Proc. 2015; 90(10): 1440\u20131454.","DOI":"10.1016\/j.mayocp.2015.08.010"},{"issue":"3","key":"6910_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O\u2019Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164\u201372.","journal-title":"N Engl J Med"},{"key":"6910_CR21","unstructured":"Bolarinwa RA, Olowookere SA, Owojuyigbe TO, Origbo EC, Durosinmi MA. Challenges to care and Medication adherence of patients with chronic myeloid leukemia in a resource-limited setting: a qualitative study. J Patient Exp: 1\u20136."},{"issue":"1","key":"6910_CR22","first-page":"1","volume":"13","author":"A Oladeji","year":"2017","unstructured":"Oladeji A, Atalabi O, Jimoh M, Ntekim I, Elumelu T. Delay in Presentation of Cancer patients for diagnosis and management: an Institutional Report. Inter J Oncol. 2017;13(1):1\u20137.","journal-title":"Inter J Oncol"},{"key":"6910_CR23","first-page":"15","volume":"5","author":"FA Bhatti","year":"2012","unstructured":"Bhatti FA, Ahmed S, Ali N. Clinical and hematological features of 335 patients of chronic myelogenous leukemia diagnosed at single centre in northern Pakistan. Clinical Medicine insights. J Blood Disord. 2012;5:15\u201324.","journal-title":"J Blood Disord"},{"key":"6910_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/908708","volume":"2015","author":"AA Oyekunle","year":"2015","unstructured":"Oyekunle AA, Bolarinwa RA, Oyelese TO, Salawu L, Durosinmi MA. Determinants of overall and progression free-survival of Nigerian patients with Philadelphia positive chronic myeloid leukaemia. Adv Hematol. 2015;2015:1\u20135.","journal-title":"Adv Hematol"},{"issue":"679","key":"6910_CR25","first-page":"1","volume":"10","author":"CK Lakshmaiah","year":"2016","unstructured":"Lakshmaiah CK, Govind BK, Aditi HT, Lokanatha D, Linu AJ, Suresh BM, et al. Prognostic and predictive implications of Sokal, Euro and eutosscores in chronic myeloid leukaemia in the imatinib era experience from tertiary oncology centre in Southern India. Ecancer. 2016;10(679):1\u201311.","journal-title":"Ecancer"},{"key":"6910_CR26","unstructured":"Hamadeh N, Van Pompaey C, Metreau E et al. New World Bank country classifications by income level: 2022\u20132023 [online]. https:\/\/blogs.worldbank.org\/opendata\/new-world-bank-country-classifications-income-level-2022-2023. Accessed August 1, 2024."},{"issue":"3","key":"6910_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442\u201359.","journal-title":"Am J Hematol"},{"issue":"3","key":"6910_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5430\/jhm.v2n3p8","volume":"2","author":"E G\u00fcrkan","year":"2012","unstructured":"G\u00fcrkan E, Paydas S. Comparison of long-term outcome of early versus late chronic phase imatinib receivers. J Hematol Malignancies. 2012;2(3):8\u201317.","journal-title":"J Hematol Malignancies"},{"issue":"6","key":"6910_CR29","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","volume":"117","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S, Shan J, Garcia-Manero G, Wieder W, et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood. 2011;117(6):1822\u20137.","journal-title":"Blood"},{"issue":"Supplement 1","key":"6910_CR30","doi-asserted-by":"publisher","first-page":"102368","DOI":"10.1016\/j.esmoop.2024.102368","volume":"9","author":"IO Ahmed","year":"2024","unstructured":"Ahmed IO, Asafa M, Bolarinwa R, Adedeji T, Asaleye M, Adesunkanmi O. Imatinib induced thyroid dysfunction in BCR::ABL1-positive chronic myeloid leukemia (CML) patients: Sokal score as a predictor. ESMO Open. 2024;9(Supplement 1):102368.","journal-title":"ESMO Open"},{"issue":"2","key":"6910_CR31","first-page":"123","volume":"11","author":"CE Origbo","year":"2020","unstructured":"Origbo CE, Bolarinwa RA, Oyekunle AA, Afolabi TO, Nwogoh B, Durosinmi MA. Adherence to glivec (imatinib mesylate) therapy amongst patients with chronic myeloid leukaemia. Annals Trop Pathol. 2020;11(2):123\u20137.","journal-title":"Annals Trop Pathol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-024-06910-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-024-06910-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-024-06910-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T10:08:43Z","timestamp":1725358123000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-024-06910-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6910"],"URL":"https:\/\/doi.org\/10.1186\/s13104-024-06910-9","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics and Research Committee of the Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria. Consent to participate did not apply to this study due to its retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}